Increased Carrier Prevalence Of Deficient Cyp2C9, Cyp2C19 and Cyp2D6 Alleles in Depressed Patients Referred to a Tertiary Psychiatric Hospital

• Murray CJ , LopezAD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study.Lancet349 , 1498–1504 (1997).
   PubMed Web of Science ®Google Scholar
• de Leon J , ArmstrongSC, CozzaKL: Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.Psychosomatics47 , 75–85 (2006).
   PubMed Web of Science ®Google Scholar
• Mrazek DA : Clinical implementation of psychiatric pharmacogenomic testing.Pers. Med.2 , 93–95 (2005).
   PubMedGoogle Scholar
• Mrazek DA : Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. The context of genetic testing in clinical psychiatric practice.CNS. Spectr.11 , 3–4 (2006).
   PubMedGoogle Scholar
• Black JL , III, O‘Kane DJ, Mrazek DA: The impact of CYP allelic variation on antidepressant metabolism: a review. Expert Opin. Drug Metab. Toxicol.3 , 21–31 (2007).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J , NickchenK, BauerM et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.Mol. Psychiatry9 , 442–473 (2004).
   PubMed Web of Science ®Google Scholar
• Susce MT , Murray-CarmichaelE, de Leon J: Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog. Neuropsychopharmacol. Biol. Psychiatry30 , 1356–1358 (2006).
   PubMed Web of Science ®Google Scholar
• Ruaño G , BlairCL, BowerB et al.: Somatic complications of psychotropic medications in a patient with multiple CYP2 drug metabolism deficiencies.Conn. Med.71 , 197–200 (2007).
   PubMedGoogle Scholar
• Ingelman-Sundberg M : Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.Pharmacogenomics. J.5 , 6–13 (2005).
   PubMed Web of Science ®Google Scholar
• Wedlund PJ , de Leon J: Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence? Clin. Pharmacol. Ther.75 , 373–375 (2004).
   PubMed Web of Science ®Google Scholar
• LLerena A , EdmanG, CobaledaJ, BenitezJ, SchallingD, BertilssonL: Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6.Acta Psychiatr. Scand.87 , 23–28 (1993).
   PubMed Web of Science ®Google Scholar
• LLerena A , BereczR, DoradoP, GonzalezAP, Penas-LLedoEM, De La Rubia A: CYP2C9 gene and susceptibility to major depressive disorder. Pharmacogenomics. J.3 , 300–302 (2003).
   PubMed Web of Science ®Google Scholar
• Sistonen J , SajantilaA, LaoO, CoranderJ, BarbujaniG, FuselliS: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure.Pharmacogenet. Genomics17 , 93–101 (2007).
   PubMed Web of Science ®Google Scholar
• Bradford LD : CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.Pharmacogenomics3 , 229–243 (2002).
   PubMed Web of Science ®Google Scholar
• Dahl ML : Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?Clin. Pharmacokinet.41 , 453–470 (2002).
   PubMed Web of Science ®Google Scholar
• Gervasini G , MartinezC, AgundezJA, Garcia-GamitoFJ, BenitezJ: Inhibition of cytochrome P450 2C9 activity in vitro by 5-hydroxytryptamine and adrenaline.Pharmacogenetics11 , 29–37 (2001).
   PubMedGoogle Scholar
• de Leon J , SusceMT, JohnsonM et al.: A clinical study of the association of antipsychotics with hyperlipidemia.Schizophr. Res.92 , 95–102 (2007).
   PubMed Web of Science ®Google Scholar
• Lazarou J , PomeranzBH, CoreyPN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.JAMA279 , 1200–1205 (1998).
   PubMed Web of Science ®Google Scholar
• Gurwitz JH , FieldTS, HarroldLR et al.: Incidence and preventability of adverse drug events among older persons in the ambulatory setting.JAMA289 , 1107–1116 (2003).
   PubMed Web of Science ®Google Scholar
• Weinshilboum R : Inheritance and drug response.N. Engl. J. Med.348 , 529–537 (2003).
   PubMed Web of Science ®Google Scholar
• Ernst FR , GrizzleAJ: Drug-related morbidity and mortality: updating the cost-of-illness model.J. Am. Pharm. Assoc. (Wash.)41 , 192–199 (2001).
   PubMedGoogle Scholar
• Johnson M , Markham-AbediC, SusceMT, Murray-CarmichaelE, McCollumS, de Leon J: A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment. CNS Spectr.11 , 757–760 (2006).
   PubMed Web of Science ®Google Scholar
• Ruaño G , ThompsonPD, WindemuthA et al.: Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis.Pharmacogenomics6 , 865–872 (2005).
   PubMed Web of Science ®Google Scholar
• Ruaño G , MakowskiG, WindemuthA et al.: High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital: implications for personalized drug safety.Pers. Med.3 , 131–137 (2006).
   PubMed Web of Science ®Google Scholar
• Melis R , LyonE, McMillinGA: Determination of CYP2D6, CYP2C9 and CYP2C19 genotypes with Tag-It mutation detection assays.Expert Rev. Mol. Diagn.6 , 811–820 (2006).
   PubMed Web of Science ®Google Scholar
• Gordon J , MeranteF, WeissS, ZastawnyR: Pharmacogenetic P-450 screening using the Tag-It universal bead-based array platform. In: Pharmacogenomics and Proteomics: Enabling The Practice of Personalized Medicine. Wong SH, Linder MW, Valdes R (Eds). AAC Press, Washington, DC, USA (2006).
   Google Scholar
• Yu AM , IdleJR, ByrdLG, KrauszKW, KupferA, GonzalezFJ: Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.Pharmacogenetics13 , 173–181 (2003).
   PubMedGoogle Scholar
• Facciola G , HidestrandM, von Bahr C, Tybring G: Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur. J. Clin. Pharmacol.56 , 881–888 (2001).
   PubMed Web of Science ®Google Scholar
• Wilke RA , MooreJH, BurmesterJK: Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.Pharmacogenet. Genomics15 , 415–421 (2005).
   PubMed Web of Science ®Google Scholar
• Cai WM , NikoloffDM, PanRM et al.: CYP2D6 genetic variation in healthy adults and psychiatric African–American subjects: implications for clinical practice and genetic testing.Pharmacogenomics. J.6 , 343–350 (2006).
   PubMed Web of Science ®Google Scholar
• Scott SA , EdelmannL, KornreichR, ErazoM, DesnickRJ: CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.Pharmacogenomics8 , 721–730 (2007).
   PubMed Web of Science ®Google Scholar
• Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet. Med.9 , 819–825 (2007).
   PubMed Web of Science ®Google Scholar
• Andersson T , FlockhartDA, GoldsteinDB et al.: Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.Clin. Pharmacol. Ther.78 , 559–581 (2005).
   PubMed Web of Science ®Google Scholar

▪ Website

• Ingelman-Sundberg M, Daly AK, Nebert DW: Homepage of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee (2008) www.cypalleles.ki.se
   Google Scholar